Showing 1 - 5 results of 5 for search 'Miguel López de Rodas', query time: 0.03s Refine Results
  1. 1
    Functional transcriptomic annotation and protein–protein interaction analysis identify EZH2 and UBE2C as key upregulated proteins in ovarian cancer

    Functional transcriptomic annotation and protein–protein interaction analysis identify EZH2 and UBE2C as key upregulated proteins in ovarian cancer by Sandra Martínez‐Canales, Miguel López de Rodas, Miriam Nuncia‐Cantarero, Raquel Páez, Eitan Amir, Balázs Győrffy, Atanasio Pandiella, Eva María Galán‐Moya, Alberto Ocaña

    Published 2018-05-01
    Get full text
    Article
  2. 2
    923 Characterization and clinical significance of the intra and inter-tumor spatial immune heterogeneity using 3-dimensional multiplexed phenotyping in non-small cell lung cancer

    923 Characterization and clinical significance of the intra and inter-tumor spatial immune heterogeneity using 3-dimensional multiplexed phenotyping in non-small cell lung cancer by Xiao Liu, Yi Li, Scott Gettinger, Kurt Schalper, Miguel López de Rodas, Zachary Frohock, Noelia Vilarino, Viviana Ahumada, R Krishna Murthy Karuturi, Joshy George

    Published 2023-11-01
    Article
  3. 3
    Role of tumor infiltrating lymphocytes and spatial immune heterogeneity in sensitivity to PD-1 axis blockers in non-small cell lung cancer

    Role of tumor infiltrating lymphocytes and spatial immune heterogeneity in sensitivity to PD-1 axis blockers in non-small cell lung cancer by Roy S Herbst, Vamsidhar Velcheti, Mari Mino-Kenudson, Matthew D Hellmann, David L Rimm, Kurt A Schalper, Anant Madabhushi, Justin Gainor, Germán Corredor, Miguel Lopez de Rodas, Venkata Nagineni, Arvind Ravi, Ila J Datar, Cristian Barrera, Lindsey Behlman, Jonathan W Riess

    Published 2022-06-01
    Get full text
    Article
  4. 4
    606 IMpower110: Tertiary lymphoid structures (TLS) and clinical outcomes in advanced non-small cell lung cancer (NSCLC) treated with first-line atezolizumab or chemotherapy

    606 IMpower110: Tertiary lymphoid structures (TLS) and clinical outcomes in advanced non-small cell lung cancer (NSCLC) treated with first-line atezolizumab or chemotherapy by Robert Johnston, Hartmut Koeppen, Roy S Herbst, Kurt Schalper, Filippo De Marinis, Giuseppe Giaccone, Jacek Jassem, Marcus Ballinger, Barani Kumar Rajendran, David R Spigel, Miguel López de Rodas, Minu K Srivastava, Jennifer M Giltnane, Barzin Y Nabet, David S Shames, Velimir Gayevskiy, Vy Ma, Ivette Estay, Tien Hoang, Reena Amin

    Published 2023-11-01
    Article
  5. 5
    Immune Cell Dynamics in EGFR-Mutated NSCLC Treated With Afatinib and Pembrolizumab: Results From a Phase IB Study

    Immune Cell Dynamics in EGFR-Mutated NSCLC Treated With Afatinib and Pembrolizumab: Results From a Phase IB Study by Jonathan W. Riess, MD, Matthew S. Lara, BS, Miguel Lopez de Rodas, MD, Guillaume Luxardi, PhD, Samantha Herbert, MSPH, Michiko Shimoda, PhD, Karen Kelly, MD, Alexander Meerlev, PhD, Elizabeth Moore, MD, Laurel Beckett, PhD, Arta Monjazeb, MD, PhD, Kurt Schalper, MD, PhD, Emanual Maverakis, MD, David R. Gandara, MD

    Published 2024-10-01
    Get full text
    Article

Search Tools: